ReviewFrontiers in immunology2025
The role of RNA methylation in glioma progression: mechanisms, diagnostic implications, and therapeutic value.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- METTL1/WDR4 Complex: A Novel Epitranscriptomic Target at the Crossroads of RNA Methylation and Drug Discovery.Journal of medicinal chemistry · 2026Review
- RNA 5-Methylcytosine Modification in Myocardial Fibrosis.Reviews in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma represents a highly lethal form of malignant tumour, with RNA methylation emerging as a critical regulator of its oncogenesis and progression. As a prevalent post-translational modification, methylation influences various biological functions, particularly RNA processing, by modulating splicing, transport, and degradation of both mRNAs and noncoding RNAs. Key methylation types such as N6-methyladenosine (m6A), N5-methylcytosine (m5C), N7-methylguanosine (m7G), and N1-methyladenosine (m1A) are dynamically regulated by specific enzymes known as writers, erasers, and readers. Dysregulation of these modifications contributes to glioma pathophysiology, while offering potential biomarkers for early detection and promising therapeutic targets. This review explores the mechanistic roles of RNA methylation in glioma and highlights its translational implications, aiming to advance molecular diagnostics and targeted interventions in glioma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.